The Human Antibody Core Facility is based on a technology that was developed at the Oklahoma Medical Research Foundation. The technology facilitates the production of fully human, full-length, antigen-specific monoclonal antibodies. The process can be completed in as little as 28 days post infection or immunization and creates full-length, properly paired antibodies of any desired IgG subclass. As a core facility, we have produced human monoclonals for a variety of purposes including novel diagnostics, passive immunotherapeutics and most importantly, understanding human immune responses to vaccination. We currently have a library of over nine hundred monoclonal antibodies. Known specificities include seasonal and pandemic H1N1, H3N2 and B influenza strains, S. pneumoniae capsular polysaccharide, rabies and vaccinia virus, and anthrax protective antigen (PA). In particular, our antibodies to anthrax protective antigen (PA), derived from an individual vaccinated with Anthrax Vaccine Absorbed (AVA), were carefully characterized, and two antibodies which bound to complex conformational epitopes of PA were shown to be protective against lethal toxin challenge both in vitro and in vivo. Our core facility produced these anti-PA monoclonals with previous funding as a member of the Cooperative Centers for Human Immunology during the last six years.

Public Health Relevance

We will provide this technology to the U19 projects for a variety of needs, including reagents to explore peptidoglycan (PGN)-triggered inflammation, and screening our current library of antibodies for antinucleosome specificities for experiments involving B. anthracis sepsis. This technology has been valuable during the last funding period and continues to be strongly applicable to the projects in the current proposal, as it will be instrumental in developing novel scientific tools that will facilitate the project goals.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oklahoma Medical Research Foundation
Oklahoma City
United States
Zip Code
More, Sunil; Yang, Xiaoyun; Zhu, Zhengyu et al. (2018) Regulation of influenza virus replication by Wnt/?-catenin signaling. PLoS One 13:e0191010
Hu, Zihua; Jiang, Kaiyu; Frank, Mark Barton et al. (2018) Modeling Transcriptional Rewiring in Neutrophils Through the Course of Treated Juvenile Idiopathic Arthritis. Sci Rep 8:7805
Booth, J Leland; Duggan, Elizabeth S; Patel, Vineet I et al. (2018) Gene expression profiling of primary human type I alveolar epithelial cells exposed to Bacillus anthracis spores reveals induction of neutrophil and monocyte chemokines. Microb Pathog 121:9-21
Seshadri, Sudarshan; Pope, Rosemary L; Zenewicz, Lauren A (2018) Glucocorticoids Inhibit Group 3 Innate Lymphocyte IL-22 Production. J Immunol 201:1267-1274
Girton, Alanson W; Popescu, Narcis I; Keshari, Ravi S et al. (2018) Serum Amyloid P and IgG Exhibit Differential Capabilities in the Activation of the Innate Immune System in Response to Bacillus anthracis Peptidoglycan. Infect Immun 86:
Langer, Marybeth; Girton, Alanson W; Popescu, Narcis I et al. (2018) Neither Lys- and DAP-type peptidoglycans stimulate mouse or human innate immune cells via Toll-like receptor 2. PLoS One 13:e0193207
DeVette, Christa I; Andreatta, Massimo; Bardet, Wilfried et al. (2018) NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors. Cancer Immunol Res 6:636-644
Popescu, Narcis I; Silasi, Robert; Keshari, Ravi S et al. (2018) Peptidoglycan induces disseminated intravascular coagulation in baboons through activation of both coagulation pathways. Blood 132:849-860
Fuentes-Mattei, Enrique; Giza, Dana Elena; Shimizu, Masayoshi et al. (2017) Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections. EBioMedicine 20:182-192
Dumas, Eric K; Garman, Lori; Cuthbertson, Hannah et al. (2017) Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated. Vaccine 35:3416-3422

Showing the most recent 10 out of 121 publications